TAS::75 0849::TAS DEVELOPMENT OF ALTERNATIVE AFFINITY CAPTURE REAGENTS FOR CANCE

随着蛋白质组学的发展，数以千计的候选癌症生物标志物已经被发现。为了充分验证这些候选癌症标记物并最终将其转化为临床使用，至关重要的是 建立针对这些癌症标记物的全面、高度特征化和标准化的特定结合分子集合。AvantGen的重组人快速分离技术平台 针对人类抗原的抗体非常适合这一需要。在这项第一阶段的研究中，将从抗体酵母展示文库中分离出针对10个肿瘤生物标志物的抗体，它们的亲和力和特异性将 要下定决心。在蛋白质识别、结合亲和力和检测方面，分离的抗体的性能将与商业化的单抗相当或更好。 在基于ELISA法的检测和Western印迹分析中。此外，这些重组抗体的分离和生产成本将明显低于单抗。一旦我们的可行性 在第一阶段展示了分离和生产高亲和力重组抗体的方法，该过程可以很容易地扩展到更多的癌症生物标记物。这些亲和试剂最终将提供 为癌症研究社区提供可重复性、高质量/特性化的替代蛋白质捕获试剂的宝贵资源。

With the advances in proteomics, thousands of cancer biomarker candidates have been discovered. To fully validate these candidate cancer markers and eventually translate them into clinical use, it is essential to establish a comprehensive, highly characterized and standardized collection of specific binding molecules directed against these cancer markers. AvantGen's technology platform for rapid isolation of recombinant antibodies against human antigens is well suited for this need. In this Phase I study, antibodies against 10 cancer biomarkers will be isolated from an antibody yeast display library and their affinity and specificity will be determined. The performances of the isolated antibodies will be comparable or better than those of commercially available monoclonal antibodies in terms of protein recognition, binding affinity, and detection in ELISA-based assays and Western blot analysis. In addition, the cost of isolation and production of these recombinant antibodies will be significantly lower than monoclonal antibodies. Once the feasibility of our approach in isolating and producing high affinity recombinant antibodies is demonstrated in Phase I, the process can be readily expanded for more cancer biomarkers. These affinity reagents will ultimately provide a valuable resource of reproducible, highly qualified/characterized alternative protein capture reagents for the cancer research community.